Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: a REL (Rete Ematologica Lombarda) experience.
Arcaini L, Laszlo D, Rizzi S, Balzarotti M, Antoniazzi F, Zilioli VR, Guggiari E, Farina L, Todisco E, Bonfichi M, Alamos SM, Rossi G, Martinelli G, Morra E. Arcaini L, et al. Among authors: balzarotti m. Leuk Res. 2011 Jun;35(6):712-4. doi: 10.1016/j.leukres.2010.12.036. Epub 2011 Jan 26. Leuk Res. 2011. PMID: 21276613 Clinical Trial.
Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusion.
Todisco E, Castagna L, Sarina B, Mazza R, Anastasia A, Balzarotti M, Banna G, Tirelli U, Soligo D, Santoro A. Todisco E, et al. Among authors: balzarotti m. Eur J Haematol. 2007 Apr;78(4):322-9. doi: 10.1111/j.1600-0609.2007.00814.x. Epub 2007 Jan 23. Eur J Haematol. 2007. PMID: 17253967 Clinical Trial.
Allogeneic stem cell transplantation compared with chemotherapy for poor-risk Hodgkin lymphoma.
Castagna L, Sarina B, Todisco E, Magagnoli M, Balzarotti M, Bramanti S, Mazza R, Anastasia A, Bacigalupo A, Aversa F, Soligo D, Giordano L, Santoro A. Castagna L, et al. Among authors: balzarotti m. Biol Blood Marrow Transplant. 2009 Apr;15(4):432-8. doi: 10.1016/j.bbmt.2008.12.506. Epub 2009 Feb 12. Biol Blood Marrow Transplant. 2009. PMID: 19285630 Free article.
Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy.
Castagna L, Bramanti S, Balzarotti M, Sarina B, Todisco E, Anastasia A, Magagnoli M, Mazza R, Nozza A, Giordano L, Rodari M, Rinifilo E, Chiti A, Santoro A. Castagna L, et al. Among authors: balzarotti m. Br J Haematol. 2009 May;145(3):369-72. doi: 10.1111/j.1365-2141.2009.07645.x. Epub 2009 Mar 5. Br J Haematol. 2009. PMID: 19344403 Free article.
The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi.
Rossi G, Marcheselli L, Dondi A, Bottelli C, Tucci A, Luminari S, Arcaini L, Merli M, Pulsoni A, Boccomini C, Puccini B, Micheletti M, Martinelli G, Rossi A, Zilioli VR, Bozzoli V, Balzarotti M, Bolis S, Cabras MG, Federico M. Rossi G, et al. Among authors: balzarotti m. Am J Hematol. 2015 Jan;90(1):56-61. doi: 10.1002/ajh.23872. Epub 2014 Nov 19. Am J Hematol. 2015. PMID: 25327841 Free article.
High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant.
Castagna L, Crocchiolo R, Giordano L, Bramanti S, Carlo-Stella C, Sarina B, Chiti A, Mauro E, Gandolfi S, Todisco E, Balzarotti M, Anastasia A, Magagnoli M, Brusamolino E, Santoro A. Castagna L, et al. Among authors: balzarotti m. Bone Marrow Transplant. 2015 Apr;50(4):499-504. doi: 10.1038/bmt.2014.304. Epub 2015 Jan 26. Bone Marrow Transplant. 2015. PMID: 25621797
B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL).
Balzarotti M, Brusamolino E, Angelucci E, Carella AM, Vitolo U, Russo E, Congiu A, Gotti M, Massidda S, Botto B, Annechini G, Spina M, Re A, Zilioli VR, Merli F, Salvi F, Stelitano C, Bonfichi M, Rodari M, Murru R, Magagnoli M, Anastasia A, Mazza R, Giordano L, Santoro A. Balzarotti M, et al. Leuk Lymphoma. 2016 Oct;57(10):2375-81. doi: 10.3109/10428194.2016.1140161. Epub 2016 Feb 15. Leuk Lymphoma. 2016. PMID: 26879066 Clinical Trial.
97 results